A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
for Small-cell Lung Cancer
50 locations incl. Casa Grande
Sponsor: Amgen
Sex: All·Age: 18 - 99
Code: NCT07005128·Phase 3·Recruiting·Listed Jun 2025